/

ANAB

AnaptysBio, Inc.Open

46.05+0.00 +0.01%USD

NasdaqGS · as of Oct 13, 11:21 ET · 15m delay

Open

45.53

Prev close

46.04

Day range

45.4246.13

52-week range

20.1872.36

Volume

90.00K0.16×

Mkt cap

1.38B

P/E ttm

—

Fwd P/E

9.08

EPS ttm

-0.9600

Div yield

0.00%

Earnings

Sep 21, 2026

From 52w high

−36.37%

Price Chart

Yahoo Finance · delayed

ANABOct 13, 2026O 45.53H 46.13L 45.42C 46.04+0.00 (+0.01%)Vol 90.00K

SMA 5054.04
SMA 20049.31

1Y change +120.17% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ANAB AnaptysBio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.85%
1 month: −14.53%
3 months: −26.34%
6 months: −1.64%
Year to date: +42.47%
1 year: +112.78%

Valuation & ownership

Market cap: 1.38B
Enterprise value: 1.48B
P/E (ttm): —
Forward P/E: 9.08
PEG ratio: —
Price / book: 129.34
Price / sales (ttm): 12.98
EV / EBITDA: 22.55
EPS (ttm): -0.9600
EPS (forward): 5.07
Beta (5y monthly): 0.45
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 29.90M
Float: 20.44M
Short % of float: 38.53%
Short ratio (days): 8.96
Held by insiders: 5.63%
Held by institutions: 105.16%
Avg volume (3m): 559.97K
50-day average: 54.19
200-day average: 49.24
52-week change: +112.78%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 27.5
vs 50-day SMA: −14.80%
vs 200-day SMA: −6.61%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.46%
Realised vol (20d, ann.): 32.3%
From 52-week high: −36.37%
From 52-week low: +128.17%

ANR

Analyst Consensus

8 analysts

Consensus

Strong buy

1.38 on a 1 (strong buy) – 5 (sell) scale

Mean target

87.25

+89.49% implied

Low 60.00Median 79.50High 140.00

Recommendation trend

Now8 / 0 / 0
1m ago10 / 0 / 0

DES

About AnaptysBio, Inc.

Yahoo Finance profile

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Headquarters: San Diego, CA, United States
Website: anaptysbio.com
Officers: Mr. Daniel R. Faga President, CEO & Director
Mr. Christopher M. Murphy Chief Financial Officer
Ms. Beth Mueller Senior Vice President of Human Resources
Mr. Benjamin Stone Chief Business Officer

SEAS

Seasonality · ANAB

2017–2026 · monthly returns

Strongest month Oct +20.07%Weakest month Mar −6.24%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.2	16.1	0.7	77.8	-15.3	21.3	-20.9	6.9	-11.9	-8.4			+42.5%
2025	35.4	-6.2	10.5	19.5	0.0	-0.1	10.6	-17.2	50.6	19.5	13.9	16.4	+266.2%
2024	10.2	8.2	-11.8	8.1	-1.6	4.7	39.0	9.3	-12.1	-35.4	15.4	-47.0	−38.2%
2023	-19.7	0.0	-12.6	-4.3	-8.3	6.5	-3.1	-0.2	-8.7	-9.2	-13.3	51.5	−30.9%
2022	-8.0	-4.4	-19.1	-5.4	-18.8	6.9	3.2	10.9	9.9	13.1	-4.2	12.2	−10.8%
2021	20.6	10.7	-24.9	8.4	2.2	8.6	-11.4	11.4	5.9	21.3	-1.7	7.4	+61.6%
2020	-10.6	3.0	-5.5	10.5	22.2	17.1	-19.6	-3.5	-14.9	99.7	-12.5	-16.6	+32.3%
2019	4.0	3.8	6.1	-0.5	0.1	-22.5	-4.8	-24.3	-13.9	7.8	-64.2	20.5	−74.5%
2018	4.6	16.5	-15.2	-9.9	-17.0	-8.7	10.2	13.2	12.6	-25.1	-0.2	-14.5	−36.7%
2017		40.7	16.4	-3.9	-4.1	-6.5	1.7	15.0	25.0	88.9	27.3	19.8	+494.2%

INSD

Insider Activity · ANAB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 14, 2026	Orwin John ADirector	—	1.3K	—
Jun 14, 2026	Renton Hollings CDirector	—	6K	—
Jun 14, 2026	Orwin John ADirector	—	6K	—
Jun 14, 2026	Schmid John PDirector	—	6K	—
Mar 29, 2026	Schmid John PDirector	Sale at price 55.71 - 57.40 per share.	20.6K	$1.16M
Mar 26, 2026	Faga Daniel RChief Executive Officer	Sale at price 56.61 - 65.99 per share.	17.7K	$1.09M
Mar 24, 2026	Faga Daniel RChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	34.3K	—
Feb 10, 2026	Loumeau Eric JosephOfficer	Sale at price 54.00 per share.	10K	$540.00K
Feb 10, 2026	Loumeau Eric JosephOfficer	Conversion of Exercise of derivative security at price 29.70 per share.	10K	$297.00K
Jan 14, 2026	Marquet MagdaDirector	Sale at price 48.12 - 48.85 per share.	11K	$530.53K
Jan 14, 2026	Marquet MagdaDirector	Conversion of Exercise of derivative security at price 26.11 per share.	11K	$287.21K
Jan 7, 2026	Mulroy Dennis CpaChief Financial Officer	Sale at price 44.71 per share.	2.5K	$112.45K
Jan 7, 2026	Faga Daniel RChief Executive Officer	Sale at price 44.71 per share.	14.3K	$638.50K
Jan 7, 2026	Lizzul Paul F.Officer	Sale at price 44.71 per share.	3.6K	$163.19K
Jan 7, 2026	Loumeau Eric JosephOfficer	Sale at price 44.71 per share.	2.2K	$98.81K
Jan 6, 2026	Mulroy Dennis CpaChief Financial Officer	Sale at price 45.11 per share.	1.9K	$86.07K
Jan 6, 2026	Mulroy Dennis CpaChief Financial Officer	—	6.7K	—
Jan 6, 2026	Faga Daniel RChief Executive Officer	Sale at price 45.11 per share.	9.2K	$415.10K
Jan 6, 2026	Faga Daniel RChief Executive Officer	—	26.8K	—
Jan 6, 2026	Lizzul Paul F.Officer	Sale at price 45.11 per share.	2.2K	$100.82K

13F

Investors Holding ANAB

latest 13F filings of 29 followed managers

Investors holding ANAB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$3.9M	0.01%	58.30K	−36%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ANAB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ANAB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About AnaptysBio, Inc.

Seasonality · ANAB

Insider Activity · ANAB

Congress Trades · ANAB

Investors Holding ANAB

Investors Holding ANAB

Congress Trades · ANAB

Insider Activity · ANAB

Seasonality · ANAB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About AnaptysBio, Inc.

Financial Snapshot

Earnings & Dividends

News